Skip to content
2000
Volume 17, Issue 5
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Growth factors of the bombesin/gastrin releasing peptide (BN/GRP) family play a critical role in proliferation and progression of malignancies. Inhibitors targeting GRP signalling have been developed and tested as anticancer compounds showing promising preclinical and early phase clinical results. In this review, we will discuss the molecular signaling, expression and the functional role of BN/GRP-GRPR in different cancer models and will focus on the available strategies to target BN/GRP-GRPR in cancer treatment as well as in tumour diagnosis and follow up.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450116666151001112130
2016-04-01
2025-10-26
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450116666151001112130
Loading

  • Article Type:
    Research Article
Keyword(s): Cancer; clinical trial; drug targets; neuropeptide; signaling transduction
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test